USP Announces Proposed Standard for Supply-Chain Integrity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Announces Proposed Standard for Supply-Chain Integrity


ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Pharmacopeia (USP) announced in a press release a draft standard contained in the proposed USP General Chapter <1083> Good Distribution PracticesSupply Chain Integrity. The draft standard contains best practices for ensuring that drugs can be traced to their original manufacturer, are not counterfeited or adulterated, and can be transported to their intended destination without compromising quality.

The proposed standard contains a section on importation that includes best practices for supply-chain risk management, development of effective supplier partnerships, and building a supply-chain quality system. Another section covers counterfeiting, including a definition of counterfeiting and best practices to combat counterfeit drugs and medicines. Included in the best-practices section are discussions of anticounterfeiting strategies such as the use of tamper-resistant packaging technologies and barcoding, as well as guidance for combating illegal Internet pharmacies. Finally, the guidance contains a section on diversion and theft.

In USP’s press release, Dr. Praveen Tyle, chief science officer of USP, says, “There is incentive for all players in the pharmaceutical industry—large and small companies, regulators and standards-setting bodies—to come to some agreement on hot-button issues such as track-and-trace technology and, at the larger level, to codify what constitutes a solid, universal approach to global supply-chain integrity.”

USP is seeking feedback on the draft standard, which will be posted in the Pharmacopeial Forum 38 (2), March–April 2012. The draft chapter and public comments will be the focus of the USP Supply Chain Integrity Workshop to be held on May 22–23, 2012, in Rockville, Maryland. The workshop will provide further opportunity to discuss the proposed standard and to decide if further information should be added.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here